© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
July 20, 2022
This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.
July 19, 2022
Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.
Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.
Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.
July 17, 2022
The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.
July 16, 2022
A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.
Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (
July 15, 2022
Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.
More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.
Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.
IBS Prevalence High Among Veterans
Long-Term Effectiveness of Adalimumab Reported in Patients with Noninfectious Uveitis
Biologic Agents May Reduce Risk of Mental Health Disorders in Some Patients with Psoriasis